Laboratory Corp. of America Holdings (LH) receives a strong valuation ranking of 77 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. LH has a better value than 77% of stocks based on these valuation analytics. Investors primarily focused on buy-and-hold strategies will find the valuation ranking relevant to their goals when making investment decisions.
LH gets a 77 Valuation Rank today. Find out what this means to you and get the rest of the rankings on LH!
LH has a trailing twelve month Price to Earnings (PE) ratio of 9.6. The historical average of roughly 15 shows a good value for LH stock as investors are paying lower share prices relative to the company's earnings. LH's low trailing PE ratio shows that the firm has been trading below its fair market value recently. Its trailing 12-month earnings per share (EPS) of 28.20 more than justifies the stock's current price. However, trailing PE ratios do not factor in the company's projected growth rate, resulting in many newer firms having high PE ratios due to high growth potential enticing investors despite inadequate earnings.
LH currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 1.41. The market is currently overvaluing LH in relation to its projected growth due to the PEG ratio being above the fair market value of 1. LH's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
LH's valuation metrics are weak at its current price due to a overvalued PEG ratio due to strong growth. LH's PE and PEG are worse than the market average resulting in a below average valuation score.
Click Here to get the full Report on Laboratory Corp. of America Holdings (LH) stock.